Episode 168: Analyzing Phase 2 Data for PACAP Targeting Therapy Bocunebart in Migraine

Episode 168 of the NeurologyLive^® Mind Moments^® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.

The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

In this Mind Moments episode, Jessica Ailani, MD, director of the MedStar Georgetown Headache Center, discusses emerging phase 2 data on bocunebart (Lundbeck), a PACAP-targeting monoclonal antibody being developed for migraine prevention. Presented at the 2026 American Headache Society Annual Meeting, findings from the PROCEED trial demonstrated efficacy in patients with episodic or chronic migraine who had previously failed 1 to 4 preventive therapies, including those considered treatment refractory. 

The conversation explores the efficacy and safety findings from PROCEED, pooled analyses from chronic migraine populations, and a separate study evaluating coadministration of bocunebart with ubrogepant. Ailani also discusses the potential role of PACAP-targeting therapies within the evolving migraine treatment landscape, considerations for future combination strategies, and key questions investigators will need to address as the program moves toward phase 3 development.

The stories featured in this week’s Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• New Clinical Data Reinforce Opakalim’s Potential as a Selective Antiseizure Therapy Option
• Atogepant Gains European Approval as Acute and Preventive Migraine Therapy
• Anti-PACAP Antibody Bocunebart Meets Primary Endpoint in Phase 2b Migraine Prevention Trial

EPISODE BREAKDOWN

• 1:10 – PROCEED trial efficacy in patients with prior preventive failures
• 5:10 – Safety and tolerability findings for bocunebart
• 6:30 – Coadministration data with ubrogepant and clinical implications
• 8:30 – Neurology News Network 
• 10:50 – Rationale for combining PACAP and CGRP-targeted therapies
• 13:40 – Key considerations for future phase 3 development

Click here to subscribe to the Mind Moments podcast. Be sure to leave a rating and review for the show. Thanks for listening!

Hoping to listen on your favorite podcast app? See below:

• Click here for Apple Podcasts
• Click here for Spotify
• Click here for Google Podcasts